Innate Pharma S.A.
IPHYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,660.9% | -97.8% | -42.4% | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | -322.2% | 10,634.8% | -135.5% | -14.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -515.7% | -7,734.8% | -207.1% | -48.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -439.2% | -8,951.8% | -200.6% | -43.3% |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.12 |
| % Growth | 16.7% | 3.2% | -158.3% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |